Duvelisib was the second PI3K inhibitor accredited from the FDA, also based upon a phase III randomized trial.a hundred thirty The efficacy and safety profile on the drug appear similar with Those people of idelalisib, if not a bit useful. Regarding different BTK inhibitors, there are numerous solut